ALK and non-small cell lung carcinoma: In the pathophysiology of human NSCLC, the expression of EML‐ALK fusion‐type oncogenes have been reported to increase, activating intracellular tyrosine kinases, phosphorylating their downstream substrates and promoting the signaling pathway of PI3K/AKT in tumors.23